Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050699 · ClinicalTrials.gov registry record · Phase 4
Sleep Intervention During Acute Lung Injury
A Phase 4 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01050699: Completed Phase 4 study, sponsored by University of Arizona.
NCT01050699 is a Phase 4 study that has completed, run by University of Arizona. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01050699, a Phase 4 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The central purpose of this proposal is to study the short-term effects of sedation with sympatholysis, using α2 adrenergic agent Dexmedetomidine, on sleep and inflammation in critically ill patients with Acute Lung Injury and Acute Respiratory Disorder Syndrome (ALI/ARDS). An additional objective is to determine the effect of Dexmedetomidine sedation on the in-vitro production of sleep-modulating inflammatory cytokines by peripheral blood mononuclear cells of critically ill patients with ALI/ARDS.
Interventions
- DRUG Dexmedetomidine
- DRUG Midazolam and Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-08 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
What the finished NCT01050699 record still lists
NCT01050699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT01050699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01050699 about?
NCT01050699 is a clinical study titled "Sleep Intervention During Acute Lung Injury". The central purpose of this proposal is to study the short-term effects of sedation with sympatholysis, using α2 adrenergic agent Dexmedetomidine, on sleep and inflammation in critically ill patients with Acute Lung Injury and Acute Respiratory Disorder Syndrome (ALI/ARDS). An additional objective i...
What is the current status of trial NCT01050699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2009-08. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01050699?
The interventions under investigation include: Dexmedetomidine (DRUG), Midazolam and Fentanyl (DRUG).
Who is sponsoring clinical trial NCT01050699?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01050699's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia